glp-1 obesity drug news oct 21 2025 CVS deal puts Lilly on equal footing with Novo Why GLP-1 drugs are changing

Comparator groups and exposure definitions also varied across studies, and prescription records did not always confirm that the medications were taken

10.1073/pnas.0631828100 [DOI] [PMC free article] [PubMed] [Google Scholar] 56.Yan S, Marguet D, Dobers J, Reutter W, Fan H

52 Similarly, the odds of at least 5-, 10-, 15- and 20-point improvements in all KCCQ domains were 1.6- to 2.9-fold higher among semaglutide- than placebo-treated patients

Tirzepatide enhances the body's own metabolic responses through dual incretin receptor activation

Novo Nordisk is sticking close to home for its latest GLP-1 deal, signing a $285 million partnership with fellow Danish company Ascendis Pharma to work on new therapeutics for metabolic and cardiovascular diseases